Advertisement

Life-Sciences-Europe.com
The European Life Sciences Web Portal
This is a free web portal for the life sciences in Europe and Israel... » read more
- BBB: Thena Capital MedTech Fund Held 1st Close at £27m (2025-03-21)
The British Business Bank today announces it has made a cornerstone commitment of up to £30m to THENA Capital’s inaugural UK MedTech Fund through its Enterprise Capital Funds programme. The fund has held its first close at £27m with commitments from Firebird Co... - AstraZeneca to Invest $2.5b in Beijing (2025-03-21)
> AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide > Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai AstraZeneca today announced an investment of $2.5 bi... - Oxford BioTherapeutics: Strategic Collaboration with Roche (2025-03-19)
> Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets > OBT to receive up to US$36 million upfront payments and may be eligible to receive miles... - Allogenica Secures €2.5m Grant from French Government (2025-03-19)
> Allogenica received a €2.5 million grant from the French government's France 2030 program to support the industrialization of its breakthrough universal CAR-T therapies for blood cancers. > Cost-effective, scalable CAR-T solutions: Allogenica, using its prop... - BioClec Launches with Backing from Sofinnova Partners (2025-03-18)
> Co-founded by Dr. Marco Colonna, a global expert in neuroimmunology and Alzheimer's research > Led by CEO Gabriella Camboni, an eminent serial entrepreneur with a track record of successful biotech ventures BioClec, a cutting-edge biotechnology company fo... - Sarepta: Young DMD Patient Died after Elevidys Treatment (2025-03-18)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following safety update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystr... - [iito] Announces Major Changes in Its Social Media Strategy (2025-03-18)
> [iito] ceased all activities on Twitter/X in 2023 > All social media activities today focussed on LinkedIn > Planning for a future outside of the “big” social media platforms [iito] Business Intelligence – a Germany-based business intelligence p... - Recursion Appoints N. Bumpus & E. Sun to Board of Directors (2025-03-18)
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology ... - Final Close of Sofinnova Biovelocita II Fund at €165m (2025-03-18)
> Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures > The fund has already screened over 300 projects and made several investments into new companies to catalyze transformativ... - Sofinnova & Gustave Roussy Launch Cell Therapy Firm (2025-03-18)
Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Rou...
Life-Sciences-Europe.com is your doorway to the European life sciences!
[LSE] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!
» Start here with the latest News!Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top